Hypoxia Inducible Factor 1 (HIF-1) Recruits Macrophage to Activate Pancreatic Stellate Cells in Pancreatic Ductal Adenocarcinoma

被引:69
作者
Li, Na [1 ]
Li, Yang [1 ]
Li, Zengxun [1 ]
Huang, Chongbiao [1 ]
Yang, Yanhui [2 ,3 ]
Lang, Mingxiao [1 ]
Cao, Junli [1 ]
Jiang, Wenna [1 ]
Xu, Yu [1 ]
Dong, Jie [1 ]
Ren, He [1 ]
机构
[1] Tianjin Med Univ, Canc Inst & Hosp, Dept Pancreat Canc, Key Lab Canc Prevent & Therapy,Natl Clin Res Ctr, Tianjin 300060, Peoples R China
[2] Tianjin Med Univ, Key Lab Hormones & Dev, Minist Hlth, Tianjin Key Lab Metab Dis,Tianjin Metab Dis Hosp, Tianjin 300070, Peoples R China
[3] Tianjin Med Univ, Tianjin Inst Endocrinol, Tianjin 300070, Peoples R China
来源
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES | 2016年 / 17卷 / 06期
基金
中国国家自然科学基金;
关键词
PDAC; monocytes/macrophages; PSCs; HIF-1; CCL2; MONOCYTE CHEMOATTRACTANT PROTEIN-1; TUMOR PROGRESSION; CANCER; EXPRESSION; GENE; THERAPY; MCP-1;
D O I
10.3390/ijms17060799
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Hypoxia inducible factor 1 (HIF-1) is a transcription factor composed of two subunits, namely, HIF-1 alpha and HIF-1 beta, in which HIF-1 beta is constitutively expressed. HIF-1 upregulates several hypoxia-responsive proteins, including angiogenesis factors, glycolysis solution enzymes, and cell survival proteins. HIF-1 is also associated with the degree of inflammation in the tumor region, but the exact mechanism remains unclear. This study aims to identify the molecular mechanism of recruiting monocytes/macrophages by HIF-1 alpha in pancreatic ductal adenocarcinoma (PDAC) and the effects of macrophages on pancreatic stellate cells (PSCs). Immunohistochemistry (IHC) was performed for cluster of differentiation 68 (CD68), HIF-1 alpha, and chemical chemokines 2 (CCL2). Western blot, real-time quantitative reverse transcription polymerase chain reaction (qRT-PCR), chromatin immunoprecipitation assay, and The Cancer Genome Atlas (TCGA) were used to verify the correlation between HIF-1 alpha and CCL2 at protein and nucleic acid levels. Monocytes/macrophages were co-cultured with PSCs to observe their interaction. Samples showed significant correlation between CD68 and HIF-1 alpha (t-test, p < 0.05). HIF-1 alpha recruited monocytes/macrophages by promoting CCL2 secretion. Moreover, macrophages could accelerate the activation of PSCs. HIF-1 alpha might promote inflammation and fibrosis of PDAC through CCL2 secretion, which may provide a novel target to treat PDAC patients.
引用
收藏
页数:12
相关论文
共 50 条
  • [21] MiR-142 modulates human pancreatic cancer proliferation and invasion by targeting hypoxia-inducible factor 1 (HIF-1α) in the tumor microenvironments
    Lu, Yebin
    Ji, Niandong
    Wei, Wei
    Sun, Weijia
    Gong, Xuejun
    Wang, Xitao
    BIOLOGY OPEN, 2017, 6 (02): : 252 - 259
  • [22] PLXDC1+ Tumor-Associated Pancreatic Stellate Cells Promote Desmoplastic and Immunosuppressive Niche in Pancreatic Ductal Adenocarcinoma
    Du, Yanhua
    Zhao, Yizhou
    Li, Judong
    Wang, Jiaxin
    You, Shenglan
    Zhang, Yao
    Zhang, Li
    Yang, Jihong
    Alinejad-Rokny, Hamid
    Cheng, Shujie
    Shao, Chenghao
    Zou, Duowu
    Ye, Youqiong
    ADVANCED SCIENCE, 2025,
  • [23] Prognostic Stratification Based on HIF-1 Signaling for Evaluating Hypoxic Status and Immune Infiltration in Pancreatic Ductal Adenocarcinomas
    Zhuang, Hongkai
    Wang, Shujie
    Chen, Bo
    Zhang, Zedan
    Ma, Zuyi
    Li, Zhenchong
    Liu, Chunsheng
    Zhou, Zixuan
    Gong, Yuanfeng
    Huang, Shanzhou
    Hou, Baohua
    Chen, Yajin
    Zhang, Chuanzhao
    FRONTIERS IN IMMUNOLOGY, 2021, 12
  • [24] Basement membrane destruction by pancreatic stellate cells leads to local invasion in pancreatic ductal adenocarcinoma
    Koikawa, Kazuhiro
    Ohuchida, Kenoki
    Ando, Yohei
    Kibe, Shin
    Nakayama, Hiromichi
    Takesue, Shin
    Endo, Sho
    Abe, Toshiya
    Okumura, Takashi
    Iwamoto, Chika
    Moriyama, Taiki
    Nakata, Kohei
    Miyasaka, Yoshihiro
    Ohtsuka, Takao
    Nagai, Eishi
    Mizumoto, Kazuhiro
    Hashizume, Makoto
    Nakamura, Masafumi
    CANCER LETTERS, 2018, 425 : 65 - 77
  • [25] Fibroblast growth factor receptor 1 gene amplification in pancreatic ductal adenocarcinoma
    Lehnen, Nils C.
    von Maessenhausen, Anne
    Kalthoff, Holger
    Zhou, Hui
    Glowka, Tim
    Schuette, Ute
    Hoeller, Tobias
    Riesner, Katarina
    Boehm, Diana
    Merkelbach-Bruse, Sabine
    Kirfel, Jutta
    Perner, Sven
    Guetgemann, Ines
    HISTOPATHOLOGY, 2013, 63 (02) : 157 - 166
  • [26] Activating transcription factor 4 regulates hypoxia inducible factor 1α in chronic hypoxia in pancreatic cancer cells
    Chee, Nancy T.
    Carriere, Candace H.
    Miller, Zachary
    Welford, Scott
    Brothers, Shaun P.
    ONCOLOGY REPORTS, 2023, 49 (01)
  • [27] HIF-1α expression is associated with the pathological response to neoadjuvant chemotherapy in pancreatic ductal adenocarcinoma patients and can be predicted using CECT features
    Wang, Fangqing
    Fan, Jinlei
    Lu, Fei
    Xu, Janwei
    Zhang, Hui
    Han, Junqi
    Chen, Jingjing
    Yu, Dexin
    QUANTITATIVE IMAGING IN MEDICINE AND SURGERY, 2025, 15 (01) : 662 - 675
  • [28] Involvement of hypoxia-inducible factor-1α (HIF-1α) in inhibition of benzene on mouse hematopoietic system
    Meng, Xing
    Zhang, Juan
    Yin, Lihong
    Pu, Yuepu
    JOURNAL OF TOXICOLOGY AND ENVIRONMENTAL HEALTH-PART A-CURRENT ISSUES, 2016, 79 (9-10): : 402 - 406
  • [29] Ring-truncated deguelin derivatives as potent Hypoxia Inducible Factor-1α (HIF-1α) inhibitors
    Kim, Ho Shin
    Hong, Mannkyu
    Lee, Su-Chan
    Lee, Ho-Young
    Suh, Young-Ger
    Oh, Dong-Chan
    Seo, Ji Hae
    Choi, Hoon
    Kim, Jun Yong
    Kim, Kyu-Won
    Kim, Jeong Hun
    Kim, Joohwan
    Kim, Young-Myeong
    Park, So-Jung
    Park, Hyun-Ju
    Lee, Jeewoo
    EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, 2015, 104 : 157 - 164
  • [30] Pancreatic and duodenal homeobox-1 in pancreatic ductal adenocarcinoma and diabetes mellitus
    Tang, Zhen-Chu
    Chu, Yi
    Tan, Yu-Yong
    Li, Jing
    Gao, Shan
    CHINESE MEDICAL JOURNAL, 2020, 133 (03) : 344 - 350